ATE222488T1 - Verwendung von anti-vegf-mitteln zur behandlung der endometriose - Google Patents
Verwendung von anti-vegf-mitteln zur behandlung der endometrioseInfo
- Publication number
- ATE222488T1 ATE222488T1 AT95919578T AT95919578T ATE222488T1 AT E222488 T1 ATE222488 T1 AT E222488T1 AT 95919578 T AT95919578 T AT 95919578T AT 95919578 T AT95919578 T AT 95919578T AT E222488 T1 ATE222488 T1 AT E222488T1
- Authority
- AT
- Austria
- Prior art keywords
- pct
- endometriosis
- treatment
- date
- vegf agents
- Prior art date
Links
- 201000009273 Endometriosis Diseases 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 abstract 3
- 238000004519 manufacturing process Methods 0.000 abstract 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 abstract 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000002452 interceptive effect Effects 0.000 abstract 1
- 210000003024 peritoneal macrophage Anatomy 0.000 abstract 1
- 230000007115 recruitment Effects 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Physical Or Chemical Processes And Apparatus (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9410533A GB9410533D0 (en) | 1994-05-26 | 1994-05-26 | In situ hybridisation and immuno-Chemical localisation of a growth factor |
| PCT/GB1995/001212 WO1995032708A1 (en) | 1994-05-26 | 1995-05-26 | Use of anti-vegf agents in the treatment of endometriosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE222488T1 true ATE222488T1 (de) | 2002-09-15 |
Family
ID=10755736
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT95919578T ATE222488T1 (de) | 1994-05-26 | 1995-05-26 | Verwendung von anti-vegf-mitteln zur behandlung der endometriose |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US6121230A (de) |
| EP (1) | EP0771192B1 (de) |
| JP (1) | JPH10505321A (de) |
| AT (1) | ATE222488T1 (de) |
| AU (1) | AU692874B2 (de) |
| CA (1) | CA2191070A1 (de) |
| DE (1) | DE69527847T2 (de) |
| ES (1) | ES2184800T3 (de) |
| GB (1) | GB9410533D0 (de) |
| NZ (1) | NZ285833A (de) |
| WO (1) | WO1995032708A1 (de) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998005293A2 (en) | 1996-08-02 | 1998-02-12 | The Children's Medical Center Corporation | Method of regulating the female reproductive system through angiogenesis inhibitors |
| DE69830320T2 (de) | 1997-03-07 | 2006-02-02 | The Wistar Institute Of Anatomy And Biology | Verwendung von Adenoviralen Vektoren, die PDGF oder VEGF exprimieren, ZUR HEILUNG VON GEWEBSDEFEKTEN UND ZUR INDUZIERUNG DER HYPERVASKULITÄT IN SÄUGERGEWEBEN |
| JP2002517209A (ja) * | 1998-06-04 | 2002-06-18 | リプロジェン, インコーポレイテッド | 子宮内膜症の診断および処置におけるプロサイモシンの使用 |
| US6753138B1 (en) | 1998-06-04 | 2004-06-22 | Reprogen, Inc. | Use of prothymosin in the diagnosis and treatment of endometriosis |
| ES2223705T3 (es) * | 1999-04-28 | 2005-03-01 | Board Of Regents, The University Of Texas System | Composiciones y metodos para el tratamiento de cancer mediante inhibi cion selectiva del vegf. |
| US6703020B1 (en) | 1999-04-28 | 2004-03-09 | Board Of Regents, The University Of Texas System | Antibody conjugate methods for selectively inhibiting VEGF |
| US6780594B2 (en) * | 2000-09-25 | 2004-08-24 | Schering Aktiengesellschaft | Method for in vitro diagnosis of endometriosis |
| CA2447851C (en) * | 2001-06-28 | 2012-08-28 | Domantis Limited | Dual-specific ligand and its use |
| US20050271663A1 (en) * | 2001-06-28 | 2005-12-08 | Domantis Limited | Compositions and methods for treating inflammatory disorders |
| EP1414964B1 (de) * | 2001-08-01 | 2010-03-24 | University Of Bristol | Isoform des vegfs |
| US7217570B2 (en) | 2001-08-23 | 2007-05-15 | The Wistar Institute Of Anatomy And Biology | Organotypic intestinal culture and methods of use thereof |
| DE10229379A1 (de) * | 2002-06-26 | 2004-01-29 | Schering Ag | EG-VEGF Rezeptor Antagonisten |
| US9321832B2 (en) * | 2002-06-28 | 2016-04-26 | Domantis Limited | Ligand |
| EP2135879A3 (de) * | 2002-06-28 | 2010-06-23 | Domantis Limited | Ligand |
| US7696320B2 (en) | 2004-08-24 | 2010-04-13 | Domantis Limited | Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor |
| EP1578801A2 (de) * | 2002-12-27 | 2005-09-28 | Domantis Limited | Dual-spezifischer einzeldomäne-antikörper welcher spezifisch ist für einen liganden und dessen rezeptor |
| AU2004226417B2 (en) * | 2003-03-28 | 2009-01-22 | Regeneron Pharmaceuticals, Inc. | Methods of treating diabetes by blocking VEGF-mediated activity |
| WO2004103159A2 (en) * | 2003-05-14 | 2004-12-02 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for modulating endometrium |
| GB0320238D0 (en) * | 2003-08-29 | 2003-10-01 | Medical Res Council | Treatment of disease |
| US20050214280A1 (en) * | 2004-03-02 | 2005-09-29 | Ludwig Institute For Cancer Research | Method for inhibiting tumor formation and growth |
| US8257742B2 (en) * | 2005-02-17 | 2012-09-04 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Bisphosphonates for treating endometriosis |
| EA200801170A1 (ru) * | 2005-12-01 | 2008-12-30 | Домантис Лимитед | Форматы неконкурентного доменного антитела, которые связываются с рецептором интерлейкина 1 первого типа |
| WO2007084599A2 (en) * | 2006-01-18 | 2007-07-26 | The General Hospital Corporation | Methods of increasing lymphatic function |
| KR20100040840A (ko) | 2007-06-06 | 2010-04-21 | 도만티스 리미티드 | 폴리펩티드,항체 가변 도메인 및 길항제 |
| WO2011073521A1 (en) | 2009-12-15 | 2011-06-23 | Petri Salven | Methods for enriching adult-derived endothelial progenitor cells and uses thereof |
| AU2011280969A1 (en) | 2010-07-23 | 2013-02-07 | Trustees Of Boston University | Anti-Despr inhibitors as therapeutics for inhibition of pathological angiogenesis and tumor cell invasiveness and for molecular imaging and targeted delivery |
| JO3283B1 (ar) | 2011-04-26 | 2018-09-16 | Sanofi Sa | تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI) |
| US20130022551A1 (en) | 2011-07-22 | 2013-01-24 | Trustees Of Boston University | DEspR ANTAGONISTS AND AGONISTS AS THERAPEUTICS |
| US9993427B2 (en) | 2013-03-14 | 2018-06-12 | Biorest Ltd. | Liposome formulation and manufacture |
| SG11201700284UA (en) | 2014-07-18 | 2017-02-27 | Sanofi Sa | Method for predicting the outcome of a treatment with aflibercept of a patient suspected to suffer from a cancer |
| US10877045B2 (en) * | 2015-07-21 | 2020-12-29 | Saint Louis University | Compositions and methods for diagnosing and treating endometriosis-related infertility |
| EP4146686A2 (de) | 2020-05-08 | 2023-03-15 | Regeneron Pharmaceuticals, Inc. | Vegf-traps und minitraps sowie verfahren zur behandlung von augenerkrankungen und krebs |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3733478A1 (de) * | 1987-10-01 | 1989-04-13 | Schering Ag | Antigestagen- und antioestrogenwirksame verbindungen zur geburtseinleitung und zum schwangerschaftsabbruch sowie zur behandlung gynaekologischer stoerungen und hormonabhaengiger tumore |
| ATE498632T1 (de) * | 1992-10-28 | 2011-03-15 | Genentech Inc | Verwendung von vaskulären endothelwachstumsfaktor-antagonisten |
| DK0694042T3 (da) * | 1993-03-25 | 2005-02-14 | Merck & Co Inc | Inhibitor af vaskulær endothelcellevækstfaktor |
-
1994
- 1994-05-26 GB GB9410533A patent/GB9410533D0/en active Pending
-
1995
- 1995-05-26 WO PCT/GB1995/001212 patent/WO1995032708A1/en active IP Right Grant
- 1995-05-26 AU AU25353/95A patent/AU692874B2/en not_active Ceased
- 1995-05-26 AT AT95919578T patent/ATE222488T1/de not_active IP Right Cessation
- 1995-05-26 EP EP95919578A patent/EP0771192B1/de not_active Expired - Lifetime
- 1995-05-26 US US08/750,143 patent/US6121230A/en not_active Expired - Fee Related
- 1995-05-26 JP JP8500493A patent/JPH10505321A/ja active Pending
- 1995-05-26 NZ NZ285833A patent/NZ285833A/en unknown
- 1995-05-26 ES ES95919578T patent/ES2184800T3/es not_active Expired - Lifetime
- 1995-05-26 DE DE69527847T patent/DE69527847T2/de not_active Expired - Fee Related
- 1995-05-26 CA CA002191070A patent/CA2191070A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JPH10505321A (ja) | 1998-05-26 |
| EP0771192A1 (de) | 1997-05-07 |
| NZ285833A (en) | 1999-09-29 |
| DE69527847D1 (de) | 2002-09-26 |
| AU692874B2 (en) | 1998-06-18 |
| ES2184800T3 (es) | 2003-04-16 |
| CA2191070A1 (en) | 1995-12-07 |
| US6121230A (en) | 2000-09-19 |
| AU2535395A (en) | 1995-12-21 |
| DE69527847T2 (de) | 2003-04-30 |
| WO1995032708A1 (en) | 1995-12-07 |
| EP0771192B1 (de) | 2002-08-21 |
| GB9410533D0 (en) | 1994-07-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE222488T1 (de) | Verwendung von anti-vegf-mitteln zur behandlung der endometriose | |
| TR199901172T2 (xx) | Yeni ikame edilmi� pirazol t�revleri. | |
| DE69921156D1 (de) | Verwendung von 5ht-6 antagonisten zur behandlung adhd | |
| DE69526937D1 (de) | Verwendung von methanbisphosphonsäurederivaten zur behandlung von aufgelockerten prothesen | |
| DE69925024D1 (de) | Verwendung von eph-rezeptor-antagonisten und agonisten zur behandlung von vaskulären krankheiten | |
| DE69827001D1 (de) | Gewebedezellularization | |
| DE59409832D1 (de) | Pflaster zur behandlung von nagelmykosen | |
| DE69726724D1 (de) | Tetrahydropteridine und pyridylpiperazine zur behandlung von neurologischen störungen | |
| DE60207383D1 (de) | Ibuprofen und diphenhydramin enthaltende zusammensetzungen und deren verwendung zur behandlung von schlafstörungen | |
| ATE144420T1 (de) | Verwendung von riluzol zur behandlung von parkinson und den parkinson-syndromen | |
| DE69535264D1 (de) | Verfahren zur behandlung von diabetes mittels kgf | |
| DE69915033D1 (de) | Verfahren zur keimungshemmende behandlung von knollen und zwiebeln mit eugenol und/oder isoeugenol | |
| ATE93138T1 (de) | Verwendung insulin-sensiblisierender wirkstoffe zur behandlung von hypertonie. | |
| UA35567C2 (uk) | Фармацевтичний препарат для лікування хворих з порушеннями функції коагуляції, спосіб лікування таких хворих, спосіб одержання фармацевтичного препарату | |
| ATE121287T1 (de) | Verfahren zur behandlung der alopezie. | |
| FI972703A0 (fi) | Rekombinantti IL-5-antagonisteja, jotka ovat käyttökelpoisia hoidettaessa IL-5:een liittyviä sairauksia | |
| ATE368455T1 (de) | Verwendung von (+)-tramadol, o-demethyltramadol, o-desmethyl-n-mono-desmethyl-tramadol zur therapie der harninkontinenz | |
| PT969843E (pt) | Composicoes antitussicas contendo teobromina | |
| ATE214272T1 (de) | Topische verwendung von kappa- opioidrezeptoragonisten zur behandlung von augenschmerz | |
| DE69333413D1 (de) | 5-ht2-antagonisten in der behandlung venöser zustände | |
| RS50148B (sr) | Upotreba docetaksela za lečenje hepatoćelijskog karcinoma | |
| ATE198990T1 (de) | Konjugat zur behandlung von entzündlichen erkrankungen | |
| DE69818823D1 (de) | Dipohosphonsäuresalze für die behandlung von osteoporose | |
| ATE157010T1 (de) | Amylin oder amylinanaloga enthaltende zusammensetzung, welche auch wahlweise insulin enthält, zur behandlung von anorexie und verwandten zuständen | |
| ATE320263T1 (de) | Verwendung von menschliche protein c zur herstellung eines arzneimittels zur behandlung von heparininduzierter thrombozytopenie |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |